Esophageal Cancer Treatments
Find Esophageal Cancer Treatments
Medications for Esophageal Cancer
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Esophageal Cancer.
Found 4 Approved Drugs for Esophageal Cancer
Nivolumab
Brand Names
Opdivo, Opdivo QVANTIG, Opdualag
Nivolumab
Brand Names
Opdivo, Opdivo QVANTIG, Opdualag
Form: Injection
Method of administration: Subcutaneous, Intravenous
FDA approval date: December 22, 2014
Classification: Programmed Death Receptor-1 Blocking Antibody
OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab.
Pembrolizumab
Brand Names
Keytruda, Keytruda QLEX
Pembrolizumab
Brand Names
Keytruda, Keytruda QLEX
Form: Injection
Method of administration: Subcutaneous, Intravenous
FDA approval date: January 15, 2015
Classification: Programmed Death Receptor-1 Blocking Antibody
KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma.
Yervoy
Generic Name
Ipilimumab
Yervoy
Generic Name
Ipilimumab
Form: Injection
Method of administration: Intravenous
FDA approval date: March 25, 2011
Classification: CTLA-4-directed Blocking Antibody
YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older.
Tevimbra
Generic Name
Tislelizumab-jsgr
Tevimbra
Generic Name
Tislelizumab-jsgr
Form: Injection
Method of administration: Intravenous
FDA approval date: March 14, 2024
Classification: Programmed Death Receptor-1 Blocking Antibody
TEVIMBRA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for: Esophageal Cancer as a single agent in adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.
Showing 1-4 of 4
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances